{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:32:24Z","timestamp":1792197144914,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00535-026-02393-6","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T13:00:41Z","timestamp":1774270841000},"page":"783-795","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of cardiometabolic criteria on the pathogenesis of MASLD and diagnostic performance of non-invasive tests"],"prefix":"10.1007","volume":"61","author":[{"given":"Kazuhito","family":"Kawata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1900-4389","authenticated-orcid":false,"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeang","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Seko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Chida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenao","family":"Noritake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanji","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asahiro","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwa","family":"Kawanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Notsumata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Oeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Atsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Sumida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Aishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Okanoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"2393_CR1","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966\u201386. https:\/\/doi.org\/10.1097\/HEP.0000000000000520.","journal-title":"Hepatology"},{"key":"2393_CR2","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"key":"2393_CR3","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158:1611-1625.e12. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.043.","journal-title":"Gastroenterology"},{"key":"2393_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389-97.e10. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.043.","journal-title":"Gastroenterology"},{"key":"2393_CR5","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","volume":"70","author":"TG Simon","year":"2021","unstructured":"Simon TG, Roelstraete B, Khalili H, Hagstr\u00f6m H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021;70:1375\u201382. https:\/\/doi.org\/10.1136\/gutjnl-2020-322786.","journal-title":"Gut"},{"key":"2393_CR6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","volume":"67","author":"H Hagstr\u00f6m","year":"2017","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67:1265\u201373. https:\/\/doi.org\/10.1016\/j.jhep.2017.07.027.","journal-title":"J Hepatol"},{"key":"2393_CR7","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557\u201365. https:\/\/doi.org\/10.1002\/hep.29085.","journal-title":"Hepatology"},{"key":"2393_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ijc.26338","volume":"131","author":"W Borena","year":"2012","unstructured":"Borena W, Strohmaier S, Lukanova A, et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer. 2012;131:193\u2013200. https:\/\/doi.org\/10.1002\/ijc.26338.","journal-title":"Int J Cancer"},{"key":"2393_CR9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/hep.24418","volume":"54","author":"A Berzigotti","year":"2011","unstructured":"Berzigotti A, Garcia-Tsao G, Bosch J, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology. 2011;54:555\u201361. https:\/\/doi.org\/10.1002\/hep.24418.","journal-title":"Hepatology"},{"key":"2393_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.gastro.2015.03.044","volume":"149","author":"MM Hassan","year":"2015","unstructured":"Hassan MM, Abdel-Wahab R, Kaseb A, et al. Obesity early in adulthood increases risk but does not affect outcomes of hepatocellular carcinoma. Gastroenterology. 2015;149:119\u201329. https:\/\/doi.org\/10.1053\/j.gastro.2015.03.044.","journal-title":"Gastroenterology"},{"key":"2393_CR11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/hep.30858","volume":"71","author":"JD Yang","year":"2020","unstructured":"Yang JD, Ahmed F, Mara KC, et al. Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease. Hepatology. 2020;71:907\u201316. https:\/\/doi.org\/10.1002\/hep.30858.","journal-title":"Hepatology"},{"key":"2393_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","volume":"165","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Wilson LA, Behling C, et al. Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study. Gastroenterology. 2023;165:463-472.e5. https:\/\/doi.org\/10.1053\/j.gastro.2023.04.025.","journal-title":"Gastroenterology"},{"key":"2393_CR13","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.2337\/dc22-2048","volume":"46","author":"L Castera","year":"2023","unstructured":"Castera L, Laouenan C, Vallet-Pichard A, et al. High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold. Diabetes Care. 2023;46:1354\u201362. https:\/\/doi.org\/10.2337\/dc22-2048.","journal-title":"Diabetes Care"},{"key":"2393_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","volume":"78","author":"V Ajmera","year":"2023","unstructured":"Ajmera V, Cepin S, Tesfai K, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2023;78:471\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2022.11.010.","journal-title":"J Hepatol"},{"key":"2393_CR15","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1111\/jgh.16019","volume":"37","author":"Y Seko","year":"2022","unstructured":"Seko Y, Kawanaka M, Fujii H, et al. Age-dependent effects of diabetes and obesity on liver-related events in non-alcoholic fatty liver disease: subanalysis of CLIONE in Asia. J Gastroenterol Hepatol. 2022;37:2313\u201320. https:\/\/doi.org\/10.1111\/jgh.16019.","journal-title":"J Gastroenterol Hepatol"},{"key":"2393_CR16","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/hep.25772","volume":"56","author":"R Loomba","year":"2012","unstructured":"Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56:943\u201351. https:\/\/doi.org\/10.1002\/hep.25772.","journal-title":"Hepatology"},{"key":"2393_CR17","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1161\/HYPERTENSIONAHA.120.15220","volume":"76","author":"S Ciardullo","year":"2020","unstructured":"Ciardullo S, Monti T, Sala I, et al. Nonalcoholic fatty liver disease and advanced fibrosis in US adults across blood pressure categories. Hypertension. 2020;76:562\u20138. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15220.","journal-title":"Hypertension"},{"key":"2393_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jhep.2025.08.017","volume":"84","author":"XD Zhou","year":"2026","unstructured":"Zhou XD, Lian LY, Chen QF, et al. Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD. J Hepatol. 2026;84:254\u201365. https:\/\/doi.org\/10.1016\/j.jhep.2025.08.017.","journal-title":"J Hepatol"},{"key":"2393_CR19","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.31014","volume":"71","author":"F Kanwal","year":"2020","unstructured":"Kanwal F, Kramer JR, Li L, Dai J, Natarajan Y, Yu X, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology. 2020;71:808\u201319.","journal-title":"Hepatology"},{"key":"2393_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/hepr.13890","volume":"53","author":"S Oeda","year":"2023","unstructured":"Oeda S, Seko Y, Hayashi H, et al. Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease. Hepatol Res. 2023;53:489\u201396. https:\/\/doi.org\/10.1111\/hepr.13890.","journal-title":"Hepatol Res"},{"key":"2393_CR21","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/hepr.14039","volume":"54","author":"K Nouso","year":"2024","unstructured":"Nouso K, Kawanaka M, Fujii H, et al. Validation study of age-independent fibrosis score (Fibrosis-3 index) in patients with metabolic dysfunction-associated steatotic liver disease. Hepatol Res. 2024;54:912\u201320. https:\/\/doi.org\/10.1111\/hepr.14039.","journal-title":"Hepatol Res"},{"key":"2393_CR22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/hepr.13871","volume":"53","author":"Y Seko","year":"2023","unstructured":"Seko Y, Takahashi H, Toyoda H, et al. Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: multicenter study. Hepatol Res. 2023;53:312\u201321. https:\/\/doi.org\/10.1111\/hepr.13871.","journal-title":"Hepatol Res"},{"key":"2393_CR23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.cgh.2023.11.022","volume":"22","author":"T Arai","year":"2024","unstructured":"Arai T, Takahashi H, Seko Y, et al. Accuracy of the enhanced liver fibrosis test in patients with type 2 diabetes mellitus and its clinical implications. Clin Gastroenterol Hepatol. 2024;22:789-797.e8. https:\/\/doi.org\/10.1016\/j.cgh.2023.11.022.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2393_CR24","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/hep4.1637","volume":"5","author":"H Ishiba","year":"2021","unstructured":"Ishiba H, Sumida Y, Seko Y, et al. Type IV collagen 7S is the most accurate test for identifying advanced fibrosis in NAFLD with type 2 diabetes. Hepatol Commun. 2021;5:559\u201372. https:\/\/doi.org\/10.1002\/hep4.1637.","journal-title":"Hepatol Commun"},{"key":"2393_CR25","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cgh.2022.02.059","volume":"21","author":"J Boursier","year":"2023","unstructured":"Boursier J, Canivet CM, Costentin C, et al. Impact of type 2 diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications. Clin Gastroenterol Hepatol. 2023;21:1243-1251.e12. https:\/\/doi.org\/10.1016\/j.cgh.2022.02.059.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2393_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2337\/dc19-1071","volume":"43","author":"F Bril","year":"2020","unstructured":"Bril F, McPhaul MJ, Caulfield MP, et al. Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes. Diabetes Care. 2020;43:290\u20137. https:\/\/doi.org\/10.2337\/dc19-1071.","journal-title":"Diabetes Care"},{"key":"2393_CR27","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cgh.2022.05.015","volume":"21","author":"T Ito","year":"2023","unstructured":"Ito T, Nguyen VH, Tanaka T, et al. Poor diagnostic efficacy of noninvasive tests for advanced fibrosis in obese or younger than 60 diabetic NAFLD patients. Clin Gastroenterol Hepatol. 2023;21:1013-1022.e6. https:\/\/doi.org\/10.1016\/j.cgh.2022.05.015.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2393_CR28","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321. https:\/\/doi.org\/10.1002\/hep.20701.","journal-title":"Hepatology"},{"key":"2393_CR29","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","volume":"94","author":"EM Brunt","year":"1999","unstructured":"Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467\u201374. https:\/\/doi.org\/10.1111\/j.1572-0241.1999.01377.x.","journal-title":"Am J Gastroenterol"},{"key":"2393_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/hep.27173","volume":"60","author":"P Bedossa","year":"2014","unstructured":"Bedossa P, FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60:565\u201375. https:\/\/doi.org\/10.1002\/hep.27173.","journal-title":"Hepatology"},{"key":"2393_CR31","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u2013835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323.","journal-title":"Hepatology"},{"key":"2393_CR32","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00535-025-02242-y","volume":"60","author":"T Tsutsumi","year":"2025","unstructured":"Tsutsumi T, Kawaguchi T, Fujii H, et al. Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis. J Gastroenterol. 2025;60:891\u2013904. https:\/\/doi.org\/10.1007\/s00535-025-02242-y.","journal-title":"J Gastroenterol"},{"key":"2393_CR33","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep.30626","volume":"70","author":"A Lonardo","year":"2019","unstructured":"Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70:1457\u201369. https:\/\/doi.org\/10.1002\/hep.30626.","journal-title":"Hepatology"},{"key":"2393_CR34","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.cgh.2022.01.002","volume":"21","author":"H Fujii","year":"2023","unstructured":"Fujii H, Iwaki M, Hayashi H, et al. Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: A multicenter registry-based cohort study. Clin Gastroenterol Hepatol. 2023;21:370\u20139. https:\/\/doi.org\/10.1016\/j.cgh.2022.01.002.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2393_CR35","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/hepr.14020","volume":"54","author":"M Nakano","year":"2024","unstructured":"Nakano M, Kawaguchi M, Kawaguchi T, et al. Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase >30 U\/L, exercise habits, and metabolic dysfunction\u2010associated steatotic liver disease. Hepatol Res. 2024;54:655\u201366. https:\/\/doi.org\/10.1111\/hepr.14020.","journal-title":"Hepatol Res"},{"key":"2393_CR36","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/apt.18205","volume":"60","author":"N Tamaki","year":"2024","unstructured":"Tamaki N, Kimura T, Wakabayashi SI, et al. Cardiometabolic criteria as predictors and treatment targets of liver-related events and cardiovascular events in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2024;60:1033\u201341. https:\/\/doi.org\/10.1111\/apt.18205.","journal-title":"Aliment Pharmacol Ther"},{"key":"2393_CR37","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","journal-title":"J Hepatol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02393-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02393-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02393-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:57:28Z","timestamp":1779955048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-026-02393-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2393"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02393-6","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kazuhito Kawata received honoraria from AbbVie GK. Hirokazu Takahashi received research grants from Takeda Pharmaceutical Company Limited, Sysmex Corporation, Kracie, Ltd., and MiZ Company Limited and received honoraria from Novo Nordisk Pharma Ltd., AbbVie GK, and Eli Lilly Japan K.K. Hidenori Toyoda received lecture fees from AbbVie GK, Gilead Sciences Inc., Kowa Co. Ltd., Terumo Corporation,\u00a0FUJIFILM Wako Pure Chemical Corporation, and AstraZeneca K.K. Masato Yoneda received a research grant from Gilead Sciences Inc. and received honoraria from Kowa Co. Ltd. Miwa Kawanaka received honoraria from AbbVie GK and a research grant from Fujirebio Inc. Yoshihiro Kamada received honoraria from Kowa Co. Ltd. and Sysmex Corporation and received contract research funding from Nippon Boehringer Ingelheim Co., Ltd. Yoshio Sumida received honoraria from Taisho Pharmaceutical Co., Ltd, Kowa Co. Ltd., and Novo Nordisk Pharma Ltd. Hideaki Fukushima is an employee of Siemens Healthcare Diagnostics K.K. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}